The evolution of therapeutic modalities drives the adoption of single-use technologies.
Despite its understandable hesitancy, the pharma industry is facing a need for more widespread adoption of cloud-based solutions.
Given the criticality of fill/finish processes, it is clear that automation is the next technological step.
The new CGMP facility is expected to contribute to the development of mRNA therapeutics, with a building designed for the CGMP manufacture of mRNA-based in-vivo gene editing, gene-edited cell therapies, protein replacement therapies, cancer vaccines, and infectious disease vaccines.
The facility is based on a state-of-the-art design concept that allows maximum flexibility for a multi-product, multi-platform offering.
uBriGene Biosciences will acquire Mustang Bio’s Worcester, Mass., CGT manufacturing facility in a deal worth up to $11 million, expanding its operations into the US market.
Felicity Thomas, European/Senior Editor, Pharm Tech Group, and Andy Dumelow, Head of Technical Sales, I Holland, chat about tablet tooling maintenance in this brief podcast.
Jane True, vice-president of mRNA Commercial Strategy & Innovation and Global Pandemic Security Lead, Pfizer, shares her perspective on how mRNA will shift commercial models in the pharmaceutical industry.
CATTI has launched an in-person training site at the University of Guelph in Ontario, Canada, for training personnel in cell and gene therapy manufacturing.
The new method was developed to isolate tissue-specific EVs from the blood in addition to using a workflow to analyze their diverse multi-omics content.
Synthego has opened its new GMP-compliant RNA manufacturing facility in Redwood City, Calif., for CRISPR-enabled genomics therapeutics.
The first CleanCap analog was launched in 2017, and since then, the capping technology has been incorporated in one of the first commercially approved COVID-19 vaccines.
Webinar Date/Time: Wednesday May 31, 2023 at 11am EDT | 10am CDT | 8am PDT
Webinar Date/Time: Tuesday June 13, 2023 at 11 am EDT | 4pm BST | 5pm CEST
A good understanding of tablet tooling and how to properly maintain these key parts will maximize lifespan of tools.
Aseptic techniques must be practiced throughout all stages of biologics production.
Contextualizing what type of flexibility is needed is paramount when considering cleanroom design.
Machine learning provides real-time data for process control of high-shear wet granulation.
Forge will provide adeno-associated virus (AAV) process development, toxicology, cGMP manufacturing, and analytical services to Life Bio, which will occur at Forge’s gene therapy facility in Columbus, Ohio called the Hearth.
Advanced continuous manufacturing with modular components is emerging as a preferred platform to produce APIs.
Dr. Ulrike Lemke, Head of Sterile Fill Finish at Recipharm, sat down with Grant Playter, associate editor, to discuss drug delivery forms.
The new partnership between Sandoz, a Novartis division, and Just – Evotec Biologics will aim to develop and manufacture multiple biosimilars.
According to a press release, SGS has doubled its capacity for nitrosamine testing for North American customers.
The new agreement is based off the Master Services Agreement that both companies entered in 2021 for the development, manufacture, and supply of rhenium (186Re) obisbemeda, according to a press release.
Vibha Jawa, executive director at Bristol Myers Squibb, discusses foreign epitopes recognition from what should be fully human antibody therapies.
The market potential of nucleic acid-based therapies have been pushed into the spotlight following the success of the COVID-19 vaccines.
The use of smart tools in early drug discovery can have an impact on downstream phases of drug development.
The development of CAR-T therapies for solid tumor cancers presents a myriad of challenges.
